After ringing up a key U.S. approval in September to threaten Johnson & Johnson's Zytiga, Astellas' Xtandi now has what it needs to ramp up its market-share battle in the EU, too.
Johnson & Johnson is walking away from a potential rheumatoid arthritis treatment from Astellas, nixing a deal that could have paid out at $945 million and putting the drug's stateside future in jeopardy.
Astellas and CoMentis are calling it quits on their partnership in Alzheimer's disease, as the Japanese drugmaker walks away from a deal valued at up to $760 million.
Japan's Astellas Pharma is the latest big drugmaker allured by the promise of gene therapy, mounting an R&D effort that could lead to a new treatment for an inherited eye disease.
Astellas and Medivation bagged that new Xtandi approval in prostate cancer. What next? Gear up for a head-to-head with Johnson & Johnson's Zytiga. And to do that, Medivation is expanding its sales force by 50%, Medical Marketing & Media reports
Japanese drugmaker Astellas Pharma has teamed up with Cancer Research U.K. to join forces on early-stage oncology R&D, working to identify new treatments for pancreatic cancer.
First it was good news, then it was bad news, and now it's good news again for Astellas' prostate cancer treatment Xtandi (enzalutamide) and its recommendation from the U.K.'s National Institute for Health and Care Excellence. At least it appears that way.
As Astellas Pharma and Medivation work to broaden the reach of their prostate cancer drug Xtandi, researchers have identified a biomarker that could help proactively spot patients for whom the treatment will not work.
We're accustomed to animated characters in our drug advertising. But a perky... bladder?
We're accustomed to animated characters in our drug advertising. That cheerful, buzzing Nasonex bee. The gently fluttering Lunesta moth. The droopy, sad little blob that so needs Zoloft. But a perky... bladder?